Aroa Biosurgery IPO, page-49

Quite trueregarding the respective revenue growth rates.

But then againPolonovo with a market cap over $1.6b is valued at around 80 x revenue, whereas Aroa with a market cap of $225.0m is currently valued at around 9 x revenue.

IMO Aroa wasconservatively priced at the ipo and a future valuation of 20 x revenue, (marketcap = $500.0m) in the near term is not out of the question. Subject to the impacts of covid19 on revenue.